≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Cytomegaloviral pneumonitis

DOID Endpoint Browser PheWeb

CMV_PNEUMONIA

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

557745

1. Apply sex-specific rule

None

557745

2. Check conditions

None

557745

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

2 out of 7 registries used, show all original rules.

80

4. Check minimum number of events

None

80

5. Include endpoints

None

80

6. Filter based on genotype QC (FinnGen only)

62

Control definitions (FinnGen only)

Control exclude
IBD_CMV

Extra metadata

First used in FinnGen datafreeze
DF2

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 414 182 224
Only index persons 268 122 146
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.00 0.01
Median age at first event (years)
Whole population 59.56 58.58 60.46
Only index persons 63.16 60.88 65.06

-FinnGen-

Key figures

All Female Male
Number of individuals 62 26 36
Unadjusted period prevalence (%) 0.01 0.01 0.02
Median age at first event (years) 66.93 63.74 69.23

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
66
Matched controls
660
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
J17.1*B25.0
ICD-10 Finland
Cytomegaloviral pneumonitis
+∞
55.1
45
*
B25.0
ICD-10 Finland
Cytomegaloviral pneumonitis
+∞
29.4
26
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
13.9
23.5
51
130
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
10.4
21.2
38
76
TGC00
NOMESCO Finland
Bronchial lavation
52.4
20.7
24
7
UGC12
NOMESCO Finland
Flexible bronchoscopy
23.9
20.5
30
22
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
12.0
19.7
25
32
H02AB04
ATC
methylprednisolone; systemic
9.2
18.3
32
61
127
Kela drug reimbursment
Transplant complication
224.5
17.4
17
*
L04AA06
ATC
mycophenolic acid; systemic
48.4
15.4
18
5
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
17.2
14.9
24
21
L04AD01
ATC
ciclosporin; systemic
63.5
13.5
15
*
TK800
NOMESCO Finland
Hemodialysis
32.0
13.3
17
7
B25.9
ICD-10 Finland
Cytomegaloviral disease, unspecified
+∞
12.9
12
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
12.9
12.6
23
26
C03CA01
ATC
furosemide; systemic
6.5
12.4
45
164
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
58.2
12.4
14
*
JN4AD
NOMESCO Finland
Body CT examination
6.7
12.3
26
58
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
15.4
12.1
20
18
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
12.8
11.6
21
23
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
7.0
11.5
22
44
GD1AA
NOMESCO Finland
Thorax X-ray examination
7.9
11.2
55
255
R50.9
ICD-10 Finland
Fever, unspecified
6.0
11.1
27
68
J17.3*B59
ICD-10 Finland
Pneumonia due to Pneumocystis carinii
+∞
10.7
10
*
Z94.0
ICD-10 Finland
Kidney transplant status
+∞
10.7
10
*
XW000
NOMESCO Finland
Bone marrow biopsy
18.9
10.1
15
10
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
36.0
9.8
12
*
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
+∞
9.6
9
*
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
8.8
9.5
21
33
B03XA02
ATC
darbepoetin alfa; parenteral
28.8
9.3
12
5
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
17.3
9.2
14
10
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
5.7
9.0
21
50
Z49.1
ICD-10 Finland
Extracorporeal dialysis
58.0
8.9
10
*
GCA98
NOMESCO Finland
Other bronchoscopic procedure on bronchus
58.0
8.9
10
*
A12AA04
ATC
calcium carbonate; oral
102.6
8.6
9
*
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
9.1
8.5
18
26
B25.8
ICD-10 Finland
Other cytomegaloviral diseases
+∞
8.5
8
*
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
8.5
8
*
WX882
NOMESCO Finland
High dependency care
25.9
8.3
11
5
J01MA12
ATC
levofloxacin; systemic
4.6
8.1
27
86
A11CC03
ATC
alfacalcidol; systemic
29.0
7.8
10
*
L04AX01
ATC
azathioprine; systemic
15.9
7.7
12
9
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
4.3
7.6
28
96
L04AD02
ATC
tacrolimus; systemic
89.8
7.6
8
*
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
18.5
7.5
11
7
N17.9
ICD-10 Finland
Acute renal failure, unspecified
14.3
7.4
12
10
L04AA01
ATC
[U] ciclosporin
+∞
7.4
7
*
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
+∞
7.4
7
*
B05DA
ATC
Isotonic solutions
+∞
7.4
7
*
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
+∞
7.4
7
*
KA2AT
NOMESCO Finland
Biopsy of transplanted kidney with ultrasound guidance
+∞
7.4
7
*
J01MA14
ATC
moxifloxacin; systemic
5.3
7.4
18
44
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
34.1
7.4
9
*
WX720
NOMESCO Finland
Own respiration
11.2
7.2
13
14
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
6.9
7.1
18
34
M04AA01
ATC
allopurinol; systemic
4.5
7.0
22
66
A02BC02
ATC
pantoprazole; systemic
6.1
6.9
59
383
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
44.7
6.9
8
*
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
77.0
6.5
7
*
TPH30
NOMESCO Finland
Insertion of central venous catheter through periferal vein
77.0
6.5
7
*
Z01.8
ICD-10 Finland
Other specified special examinations
4.2
6.5
23
75
WX892
NOMESCO Finland
Monitored bed care
8.1
6.5
14
21
J80
ICD-10 Finland
Adult respiratory distress syndrome
+∞
6.3
6
*
137
Kela drug reimbursment
Uraemia requiring dialysis
+∞
6.3
6
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.7
6.1
27
103
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
4.2
6.0
20
62

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
26
42
9.56
16.95
14.5
4.4
—
—
—
0
0
53
183
10.63
16.93
13.5
5.1
—
—
—
0
0
37
93
7.78
16.02
3.6
1.8
—
—
—
0
0
33
75
7.80
15.72
15.7
9.2
0.90
1.31
mmol/l
0.22
23
57
33
77
7.57
15.26
15.8
8.9
7.39
7.41
ph
0.69
23
44
21
12
24.91
15.07
3.0
1.9
—
—
—
0
0
21
12
24.91
15.07
3.0
1.9
—
—
—
0
0
21
12
24.91
15.07
3.0
1.9
—
—
—
0
0
21
12
24.91
15.07
3.0
1.9
—
—
—
0
0
50
207
6.84
11.77
21.1
6.3
—
—
—
0
0
29
75
6.11
11.65
3.1
1.5
—
—
—
0
0
17
12
18.55
11.24
2.4
2.1
—
—
—
0
0
26
70
5.48
9.79
10.0
3.6
0.47
2.07
mmol/l
1.43
17
56
31
98
5.08
9.64
2.4
1.8
—
—
—
0
0
26
72
5.31
9.44
11.6
3.5
7.36
7.39
ph
1.62
18
51
12
5
28.75
9.28
3.0
6.4
—
—
—
0
0
15
13
14.51
9.13
1.8
1.3
—
—
—
0
0
54
285
5.92
8.36
26.2
4.3
32.30
35.21
g/l
2.49
48
266
19
44
5.66
8.33
13.9
3.0
133.05
74.21
ng/l
2.02
19
38
54
298
5.47
7.55
39.3
7.7
1.20
1.20
mmol/l
0.24
48
257
13
13
12.11
7.43
3.6
4.5
—
—
—
0
0
14
17
10.12
7.27
1.8
1.4
—
—
—
0
0
10
6
19.27
6.99
2.1
1.2
—
—
—
0
0
17
43
4.98
6.65
2.2
1.9
—
—
—
0
0
22
69
4.28
6.60
3.0
1.8
—
—
—
0
0
55
328
5.06
6.45
22.3
6.5
0.17
0.20
e9/l
0.85
50
289
6
0
+∞
6.34
2.0
0.0
—
—
—
0
0
19
55
4.45
6.29
3.1
2.7
63.62
66.73
g/l
0.57
14
50
54
321
4.75
6.27
19.9
6.4
0.04
0.04
e9/l
0.11
48
275
58
387
5.11
6.00
14.1
4.8
—
—
—
0
0
12
16
8.89
5.94
2.3
1.2
—
—
—
0
0
53
319
4.36
5.85
20.3
6.4
0.73
0.59
e9/l
1.06
47
274
54
331
4.47
5.77
21.4
6.3
3.67
1.77
e9/l
0.62
49
294
16
45
4.37
5.44
3.0
2.3
—
—
—
0
0
20
67
3.85
5.39
2.2
1.6
—
—
—
0
0
5
0
+∞
5.27
1.2
0.0
—
—
—
0
0
5
0
+∞
5.27
1.0
0.0
—
—
—
0
0
5
0
+∞
5.27
5.8
0.0
—
—
—
0
0
18
57
3.97
5.23
11.7
9.3
—
—
—
0
0
45
261
3.28
4.89
8.6
2.6
—
—
estimate
—
0
0
22
84
3.43
4.84
3.0
1.6
—
—
—
0
0
19
68
3.52
4.59
8.3
3.0
19.71
7.47
umol/l
0.64
14
61
12
24
5.86
4.58
1.3
1.2
—
—
—
0
0
9
12
8.47
4.52
1.7
1.1
—
—
—
0
0
56
382
4.08
4.46
10.8
4.6
—
44.40
—
0
5
16
52
3.74
4.44
8.5
8.9
1.91
1.33
mmol/l
0.32
16
52
7
6
12.83
4.38
2.0
1.5
—
—
—
0
0
11
23
5.52
4.08
5.3
1.6
16.94
5.64
iu/ml
—
5
5
6
6
10.82
3.57
1.0
1.5
—
—
—
0
0
14
48
3.43
3.55
12.1
8.1
24.80
24.86
mmol/l
0.02
14
48
59
458
3.71
3.50
35.9
8.7
99.39
79.07
u/l
0.62
59
434
13
39
3.89
3.47
10.0
3.2
23.72
23.93
mmol/l
0.11
13
39
6
7
9.27
3.33
2.0
2.9
—
—
—
0
0
32
180
2.51
3.29
7.3
2.9
0.53
0.45
e6/l
0.07
25
132
32
181
2.49
3.24
5.1
3.2
—
—
—
0
0
35
208
2.45
3.16
7.3
3.0
28.75
34.17
e6/l
0.10
28
158
6
8
8.10
3.12
7.0
1.9
3.81
4.81
e9/l
—
6
8
32
186
2.40
3.00
2.2
1.7
15.13
21.60
nmol/l
3.56
26
146
27
146
2.44
2.96
16.5
5.3
—
—
—
0
0
6
9
7.19
2.93
2.7
2.4
21.43
34.97
%
—
6
9
6
9
7.19
2.93
2.2
1.3
—
—
—
0
0
8
18
4.90
2.90
9.4
2.9
—
—
—
0
0
7
14
5.45
2.81
5.4
3.0
66.16
60.80
%
—
7
14
7
14
5.45
2.81
12.6
1.5
55.43
63.31
%
—
7
14
5
6
8.88
2.79
2.4
7.5
—
—
—
0
0
5
6
8.88
2.79
1.2
8.3
1650.20
428.83
mg
—
5
6
6
10
6.47
2.76
7.2
2.5
1.33
3.10
%
—
6
10
35
221
2.24
2.62
8.7
3.2
6.59
8.08
mmol/l
1.19
30
181
25
137
2.33
2.61
2.8
1.5
2.26
2.64
g/l
0.47
18
76
5
7
7.60
2.59
4.4
1.3
—
—
—
0
0
36
232
2.21
2.54
9.9
3.9
7.53
80.63
e6/l
1.34
28
166
19
93
2.46
2.53
8.6
8.2
104.53
103.92
mmol/l
0.18
19
93
26
147
2.27
2.51
1.7
1.4
—
—
—
0
0
6
12
5.38
2.46
9.2
1.8
1.15
0.99
%
—
6
7
14
61
2.64
2.34
1.9
1.3
—
—
—
0
0
9
29
3.43
2.33
15.9
3.7
—
—
—
0
0
21
112
2.28
2.30
1.9
1.7
1170.07
1327.62
nmol/l
0.29
15
86
39
267
2.13
2.28
6.2
2.7
333.69
151.44
ug/l
1.85
39
246
38
260
2.09
2.20
2.6
2.1
96.10
97.64
pmol/l
0.09
21
137
14
63
2.55
2.19
6.6
3.3
5.07
4.27
kpa
0.78
14
63
39
278
1.98
1.93
39.8
14.9
0.00
0.00
e9/l
-0.00
25
229
32
215
1.95
1.86
8.9
3.2
196.59
57.89
mg/l
0.92
26
142
5
12
4.41
1.86
3.8
1.3
87.32
90.38
%
—
5
12
28
180
1.96
1.85
4.6
2.5
—
—
—
0
0
36
256
1.89
1.74
7.0
3.7
6.31
6.24
ph
0.14
21
132
7
25
3.01
1.70
11.4
3.5
7.44
7.43
ph
—
7
25
32
222
1.86
1.64
10.2
4.0
53.77
9.47
mg/mmol
0.78
25
136
7
26
2.89
1.63
1.6
4.1
62.71
349.60
u/ml
—
7
20
7
26
2.89
1.63
2.0
1.2
—
—
—
0
0
6
20
3.19
1.62
8.8
2.4
2.50
1.89
mmol/l
—
6
14
6
20
3.19
1.62
8.8
2.4
4.67
4.90
kpa
—
6
20
6
20
3.19
1.62
8.8
2.4
7.93
8.48
kpa
—
6
20
5
16
3.29
1.46
1.2
1.4
—
58.00
titre
—
0
5
7
29
2.58
1.43
3.7
5.0
36.90
36.99
°c
—
7
29
42
328
1.77
1.37
8.3
4.2
0.00
0.00
estimate
-0.00
11
81
6
24
2.64
1.33
1.5
1.2
—
—
—
0
0
42
330
1.75
1.33
8.2
4.2
0.00
0.00
estimate
-0.00
11
80
24
161
1.77
1.32
7.7
3.1
—
0.29
—
0
7
22
144
1.79
1.31
2.0
1.7
518.00
458.77
pmol/l
0.53
15
124
42
332
1.73
1.28
8.4
4.2
0.00
0.00
estimate
—
10
75
26
181
1.72
1.25
7.2
3.6
0.00
0.00
estimate
—
8
61
5
19
2.76
1.24
6.8
2.2
65.20
62.72
u/ml
—
5
19
6
26
2.43
1.21
15.7
2.4
7.82
8.30
kpa
—
6
26
8
39
2.19
1.20
6.5
3.0
0.66
0.66
%
—
8
39
8
39
2.19
1.20
6.5
3.0
0.84
1.20
%
—
8
39
35
268
1.65
1.16
6.3
4.4
32.12
27.36
ng/l
0.38
29
202
5
21
2.49
1.11
1.6
1.5
—
—
—
0
0
5
22
2.37
1.05
11.8
2.2
13.08
16.25
%
—
5
22
5
22
2.37
1.05
1.2
1.2
—
—
—
0
0
0
29
0.00
1.00
0.0
1.3
—
—
—
0
0
11
63
1.90
0.97
12.5
1.7
322.09
136.24
ug/g
0.71
11
49
8
45
1.88
0.88
20.1
4.5
7.39
7.39
ph
—
8
33
28
217
1.50
0.81
2.5
2.1
—
—
—
0
0
31
247
1.48
0.78
7.5
4.2
0.00
0.00
estimate
—
10
67
5
23
2.27
0.78
11.4
2.3
87.94
90.26
%
—
5
23
5
24
2.17
0.76
9.0
2.2
112.20
127.79
g/l
—
5
19
9
58
1.64
0.73
9.3
4.1
—
—
—
0
0
8
52
1.61
0.62
1.1
1.2
—
—
—
0
0
0
23
0.00
0.59
0.0
1.1
—
—
—
0
0
18
230
0.70
0.57
3.0
3.6
—
—
—
0
0
6
39
1.59
0.54
2.8
1.5
—
—
—
0
0
61
578
1.73
0.49
84.9
20.7
138.69
139.61
mmol/l
1.67
61
570
61
580
1.68
0.49
86.6
20.6
4.03
3.98
mmol/l
0.74
61
571
5
31
1.66
0.44
2.6
2.3
—
—
—
0
0
0
15
0.00
0.42
0.0
1.7
—
—
—
0
0
0
16
0.00
0.41
0.0
1.6
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
1.50
—
0
18
9
70
1.33
0.39
1.3
1.3
—
—
—
0
0
10
73
1.44
0.37
2.1
1.2
—
—
—
0
0
22
190
1.24
0.28
12.4
5.8
—
—
—
0
0
60
580
1.38
0.26
67.7
16.4
—
—
—
0
0
24
269
0.83
0.24
4.0
6.2
1.93
1.93
ug/l
0.00
24
240
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
23
206
1.18
0.19
6.9
4.2
0.00
0.00
estimate
—
9
73
7
61
1.16
0.18
1.9
1.4
—
—
—
0
0
61
595
1.33
0.18
87.6
23.1
116.75
81.06
umol/l
2.69
61
589
25
235
1.10
0.09
5.5
4.0
—
—
—
0
0
24
249
0.94
0.03
2.9
2.0
1.36
1.42
mmol/l
0.23
24
200
43
438
0.95
0.02
3.5
4.2
15.24
14.81
pmol/l
0.58
43
389
54
547
0.93
0.02
7.5
5.4
6.16
6.03
mmol/l
0.24
49
490
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
3.2
—
6.54
—
0
5
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
3.65
—
0
6
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
60
591
1.17
-0.00
47.4
12.8
26.00
25.77
u/l
0.04
60
576
0
7
0.00
-0.00
0.0
1.0
—
210.40
—
0
7
8
84
0.95
-0.00
1.8
1.3
—
—
—
0
0
61
602
1.18
-0.00
104.5
27.0
235.92
240.85
e9/l
0.17
61
594
61
602
1.18
-0.00
102.6
27.0
4.06
4.49
e12/l
4.69
61
590
61
602
1.18
-0.00
103.0
27.2
9.45
6.63
e9/l
2.85
61
590

Mortality – FinRegistry

↥

Association

Association between endpoint CMV_PNEUMONIA and mortality.

Females

Parameter HR [95% CI] p-value
CMV_PNEUMONIA 10.122 [4.72, 21.71] < 0.001
Birth year 0.993 [0.98, 1.0] 0.105

During the follow-up period (1.1.1998 — 31.12.2019), 54 out of 114 females with CMV_PNEUMONIA died.

Males

Parameter HR [95% CI] p-value
CMV_PNEUMONIA 5.501 [3.25, 9.32] < 0.001
Birth year 0.984 [0.97, 0.99] 0.002

During the follow-up period (1.1.1998 — 31.12.2019), 55 out of 111 males with CMV_PNEUMONIA died.

Mortality risk

Mortality risk for people of age

years, who have CMV_PNEUMONIA.

N-year risk Females Males
1 0.989% 1.02%
5 5.265% 5.537%
10 13.387% 14.094%
15 25.115% 23.732%
20 38.525% 37.855%

Relationships between endpoints

↥

Index endpoint: CMV_PNEUMONIA – Cytomegaloviral pneumonitis

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data